Adagene (ADAG) to Post Earnings on Wednesday

Adagene (NASDAQ:ADAG) is anticipated to post its Q2 2026 resultson Wednesday, September 2nd. Analysts expect Adagene to announce earnings of ($0.22) per share and revenue of $17.50 million for the quarter. Individuals are encouraged to explore the company’s upcoming Q2 2026 earning overview page for the latest details on the call scheduled for Wednesday, August 12, 2026 at 4:00 PM ET.

Adagene Stock Performance

NASDAQ:ADAG opened at $3.68 on Monday. The business has a 50 day simple moving average of $3.89 and a 200 day simple moving average of $3.70. The company has a debt-to-equity ratio of 0.01, a quick ratio of 3.07 and a current ratio of 5.02. Adagene has a 12-month low of $1.30 and a 12-month high of $4.85.

Insider Transactions at Adagene

In other Adagene news, CEO Peter Luo bought 22,966 shares of the stock in a transaction that occurred on Tuesday, August 4th. The shares were purchased at an average cost of $3.65 per share, for a total transaction of $83,825.90. Following the transaction, the chief executive officer directly owned 67,966 shares in the company, valued at $248,075.90. The trade was a 51.04% increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Over the last three months, insiders purchased 25,245 shares of company stock valued at $92,344. Corporate insiders own 21.20% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently modified their holdings of the business. Marex Group plc acquired a new position in shares of Adagene during the second quarter valued at $47,000. SmartHarvest Portfolios LLC acquired a new stake in Adagene in the fourth quarter worth about $73,000. Citadel Advisors LLC acquired a new stake in Adagene in the third quarter worth about $80,000. Finally, Exome Asset Management LLC bought a new position in Adagene in the 4th quarter valued at about $2,004,000. Institutional investors own 9.51% of the company’s stock.

Analyst Ratings Changes

Several brokerages have recently issued reports on ADAG. Guggenheim reissued a “buy” rating and set a $10.00 price target on shares of Adagene in a report on Tuesday, July 14th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Adagene in a report on Friday, July 17th. One equities research analyst has rated the stock with a Strong Buy rating, one has given a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $10.00.

Adagene Company Profile

Adagene Inc, headquartered in Suzhou, China, is a clinical-stage biopharmaceutical company specializing in the discovery and development of antibody-based therapeutics for cancer and immune-related diseases. Founded in 2017, the company leverages its proprietary immunome technology platform to mine human antibody repertoires and engineer novel monospecific and bispecific antibodies. Adagene’s pipeline includes multiple candidates in preclinical and early clinical development, with a focus on targeting tumor microenvironments and modulating immune checkpoints to enhance anti-tumor efficacy.

At the core of Adagene’s research and development efforts is its Bihanc™ antibody platform, which combines combinatorial phage display, structure-based design and artificial intelligence to optimize binding affinity, specificity and developability.